| aGvHD | acute graft-versus-host disease |
| cGvHD | chronic graft-versus-host disease |
| aPC | activated protein C |
| AT1R | angiotensin 1 receptor |
| AR | adrenergic receptor |
| BM | bone marrow |
| BMP | bone morphogenetic protein |
| CAR | chimeric antigen receptor |
| CB | cannabinoid receptor |
| DIC | disseminated intravascular coagulation |
| DKT | Dai-kenchu-to |
| ECS | endocannabinoid system |
| G-CSF | granulocyte colony-stimulating factor |
| GTEx | Genotype-Tissue expression |
| GF | graft failure |
| GPCR | G protein-coupled receptor |
| GRK | GPCR-related kinases |
| GvL | graft-versus-leukemia |
| HPA | Human Protein Atlas |
| HSC | hematopoietic stem cell |
| HSCT | hematopoietic stem cell transplantation |
| IPS | idiopathic pneumonia syndrome |
| MCT | Monocrotaline |
| MM | multiple myeloma |
| NHL | non-Hodgkin lymphoma |
| NRM | non-relapse mortality |
| P2Y2 | P2Y purinoreceptor 2 |
| PAF | platelet-activating factor |
| PAR | protease-activated receptor |
| PB | peripheral blood |
| PBSC | peripheral blood stem cell |
| PRISMA | Preferred Reporting Items for Systematic Reviews and Meta-Analyses |
| RANTES | Regulated on Activation, Normal T Cell Expressed and Secreted (CCL5) |
| 7TMR | seven trans-membrane spanning receptor |
| SCFA | short-chain fatty acid |
| SMO | Smoothened |
| SOS | sinusoidal obstruction syndrome |
| SPM | specialized pro-resolving mediators |
| THC | tetrahydrocannabinol |
| TM(E5) | thrombomodulin (fifth epidermal growth factor-like region) |
| Tregs | regulatory T cells |
| TRM | transplantation- or treatment-related mortality |
| TRTs | treatment-related toxicities |
| VOD | veno-occlusive disease (the term formerly used for SOS) |